Anupam Rasayan India Limited reported unaudited consolidated results for the quarter ended 31 December 2025, with total revenue of Rs5,145 million (mn), representing 33 per cent year-on-year growth. The company recorded continued momentum in its custom synthesis and specialty chemicals business and attributed the increase to stronger demand across domestic and global markets. The board approved the results in Surat and the performance reflects the company focus on advanced process capabilities. EBITDA including other income stood at Rs1,296 mn for the quarter, up seven per cent year-on-year, translating into a 25.20 per cent EBITDA margin. Profit after tax was Rs606 mn, up 12 per cent compared with the prior year quarter. The quarter results benefited from operating leverage and product mix improvements that supported margin expansion despite cost pressures. For the nine months of financial year 2026 the company delivered consolidated revenue of Rs17,297 mn and EBITDA of Rs4,024 mn, signalling robust year-on-year growth across periods. The managing director noted that the company continued to build scale and capability through strategic initiatives during the period. A definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States was signed, which the company said will strengthen its global footprint, enhance advanced custom synthesis capability and deepen access to regulated markets and innovator customers in North America. Anupam Rasayan operates six manufacturing facilities in Gujarat, India, with four sites at Sachin in Surat and two at Jhagadia in Bharuch, and an aggregate installed capacity of about 30,000 tonne (t) as of 31 March 2025. The company serves a diverse base of customers, including multinational firms, and focuses on multistep synthesis and complex chemical reactions to support agrochemical, personal care and pharmaceutical applications. Investor relations and public relations contacts were provided for further enquiries.